These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15761868)

  • 1. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
    Koizumi F; Shimoyama T; Taguchi F; Saijo N; Nishio K
    Int J Cancer; 2005 Aug; 116(1):36-44. PubMed ID: 15761868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
    Taguchi F; Koh Y; Koizumi F; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2004 Dec; 95(12):984-9. PubMed ID: 15596048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
    Ando K; Ohmori T; Inoue F; Kadofuku T; Hosaka T; Ishida H; Shirai T; Okuda K; Hirose T; Horichi N; Nishio K; Saijo N; Adachi M; Kuroki T
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8872-9. PubMed ID: 16361577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
    Zhou G; Zhang F; Guo Y; Huang J; Xie Y; Yue S; Chen M; Jiang H; Li M
    Biomed Pharmacother; 2017 Jan; 85():113-119. PubMed ID: 27930974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
    Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
    BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
    Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
    Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells.
    Ji Y; Ma SL; Zhang YP; Tang JJ; Wu YM; Lu YJ
    Anticancer Drugs; 2009 Oct; 20(9):832-7. PubMed ID: 19620837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R; Jiang H; Li J; Liu X; Xu H
    Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
    Ogino A; Kitao H; Hirano S; Uchida A; Ishiai M; Kozuki T; Takigawa N; Takata M; Kiura K; Tanimoto M
    Cancer Res; 2007 Aug; 67(16):7807-14. PubMed ID: 17699786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
    Kokubo Y; Gemma A; Noro R; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Shibuya M; Kudoh S
    Br J Cancer; 2005 May; 92(9):1711-9. PubMed ID: 15870831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
    Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
    PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
    Zhou J; Hu Q; Zhang X; Zheng J; Xie B; Xu Z; Zhang W
    Oncol Rep; 2018 Apr; 39(4):1783-1792. PubMed ID: 29393480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
    Ochi N; Takigawa N; Harada D; Yasugi M; Ichihara E; Hotta K; Tabata M; Tanimoto M; Kiura K
    Exp Cell Res; 2014 Mar; 322(1):168-77. PubMed ID: 24440771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
    Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.